BIOE Bio Essence Corp. Forecast, Technical & Fundamental Analysis

BIOE's RSI Indicator recovers from oversold territory

The RSI Indicator for BIOE moved out of oversold territory on September 16, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 10 similar instances when the indicator left oversold territory. In of the 10 cases the stock moved higher. This puts the odds of a move higher at .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BIOE just turned positive on September 23, 2025. Looking at past instances where BIOE's MACD turned positive, the stock continued to rise in of 10 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Momentum Indicator moved below the 0 level on September 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BIOE as a result. In of 21 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

BIOE moved below its 50-day moving average on September 02, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BIOE crossed bearishly below the 50-day moving average on September 09, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.941). P/E Ratio (0.000) is within average values for comparable stocks, (73.534). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.959). BIOE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (6.203) is also within normal values, averaging (45.936).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BIOE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.